Repligen Co. (NASDAQ:RGEN) Shares Bought by Forsta AP Fonden

Forsta AP Fonden boosted its holdings in Repligen Co. (NASDAQ:RGEN) by 6.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,900 shares of the biotechnology company’s stock after acquiring an additional 800 shares during the quarter. Forsta AP Fonden’s holdings in Repligen were worth $1,626,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of RGEN. Andra AP fonden acquired a new position in shares of Repligen in the 2nd quarter worth $25,000. YHB Investment Advisors Inc. bought a new position in Repligen during the first quarter valued at about $26,000. International Assets Investment Management LLC acquired a new stake in Repligen in the 2nd quarter worth approximately $33,000. Lazard Asset Management LLC grew its stake in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares during the last quarter. Finally, Principal Securities Inc. bought a new position in shares of Repligen in the fourth quarter worth about $48,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

RGEN has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Wednesday, June 26th. Stephens reiterated an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Royal Bank of Canada reissued an “outperform” rating and issued a $190.00 target price on shares of Repligen in a research note on Wednesday, July 31st. Guggenheim began coverage on Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating on the stock. Finally, Wells Fargo & Company began coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $188.38.

Repligen Price Performance

NASDAQ RGEN opened at $140.00 on Tuesday. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The firm’s 50 day moving average is $145.84 and its 200-day moving average is $156.46. The company has a market capitalization of $7.82 billion, a PE ratio of 560.00, a price-to-earnings-growth ratio of 4.20 and a beta of 0.94. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million for the quarter, compared to analysts’ expectations of $154.11 million. During the same period in the previous year, the firm posted $0.53 EPS. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. Equities research analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.